» Articles » PMID: 35651633

Human Brain-Based Models Provide a Powerful Tool for the Advancement of Parkinson's Disease Research and Therapeutic Development

Overview
Journal Front Neurosci
Date 2022 Jun 2
PMID 35651633
Authors
Affiliations
Soon will be listed here.
Abstract

Parkinson's disease (PD) is the second most common neurodegenerative disease and affects approximately 2-3% of the population over the age of 65. PD is characterised by the loss of dopaminergic neurons from the substantia nigra, leading to debilitating motor symptoms including bradykinesia, tremor, rigidity, and postural instability. PD also results in a host of non-motor symptoms such as cognitive decline, sleep disturbances and depression. Although existing therapies can successfully manage some motor symptoms for several years, there is still no means to halt progression of this severely debilitating disorder. Animal models used to replicate aspects of PD have contributed greatly to our current understanding but do not fully replicate pathological mechanisms as they occur in patients. Because of this, there is now great interest in the use of human brain-based models to help further our understanding of disease processes. Human brain-based models include those derived from embryonic stem cells, patient-derived induced neurons, induced pluripotent stem cells and brain organoids, as well as post-mortem tissue. These models facilitate analysis of disease mechanisms and it is hoped they will help bridge the existing gap between bench and bedside. This review will discuss the various human brain-based models utilised in PD research today and highlight some of the key breakthroughs they have facilitated. Furthermore, the potential caveats associated with the use of human brain-based models will be detailed.

Citing Articles

Intercellular transmission of alpha-synuclein.

Wu S, Schekman R Front Mol Neurosci. 2024; 17:1470171.

PMID: 39324117 PMC: 11422390. DOI: 10.3389/fnmol.2024.1470171.


Landscape of human organoids: Ideal model in clinics and research.

Han X, Cai C, Deng W, Shi Y, Li L, Wang C Innovation (Camb). 2024; 5(3):100620.

PMID: 38706954 PMC: 11066475. DOI: 10.1016/j.xinn.2024.100620.


Advanced 3D Models of Human Brain Tissue Using Neural Cell Lines: State-of-the-Art and Future Prospects.

Fabbri R, Cacopardo L, Ahluwalia A, Magliaro C Cells. 2023; 12(8).

PMID: 37190089 PMC: 10136913. DOI: 10.3390/cells12081181.


Evidence for Oxidative Pathways in the Pathogenesis of PD: Are Antioxidants Candidate Drugs to Ameliorate Disease Progression?.

Leathem A, Ortiz-Cerda T, Dennis J, Witting P Int J Mol Sci. 2022; 23(13).

PMID: 35805928 PMC: 9266756. DOI: 10.3390/ijms23136923.

References
1.
Olgiati S, Quadri M, Fang M, Rood J, Saute J, Chien H . DNAJC6 Mutations Associated With Early-Onset Parkinson's Disease. Ann Neurol. 2015; 79(2):244-56. DOI: 10.1002/ana.24553. View

2.
Park I, Arora N, Huo H, Maherali N, Ahfeldt T, Shimamura A . Disease-specific induced pluripotent stem cells. Cell. 2008; 134(5):877-86. PMC: 2633781. DOI: 10.1016/j.cell.2008.07.041. View

3.
Chambers S, Fasano C, Papapetrou E, Tomishima M, Sadelain M, Studer L . Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nat Biotechnol. 2009; 27(3):275-80. PMC: 2756723. DOI: 10.1038/nbt.1529. View

4.
Haining R, Achat-Mendes C . Neuromelanin, one of the most overlooked molecules in modern medicine, is not a spectator. Neural Regen Res. 2017; 12(3):372-375. PMC: 5399705. DOI: 10.4103/1673-5374.202928. View

5.
Kim T, Piao J, Koo S, Kriks S, Chung S, Betel D . Biphasic Activation of WNT Signaling Facilitates the Derivation of Midbrain Dopamine Neurons from hESCs for Translational Use. Cell Stem Cell. 2021; 28(2):343-355.e5. PMC: 8006469. DOI: 10.1016/j.stem.2021.01.005. View